Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative

Research and development

Amortization of acquired intangibles

Restructuring - operating expenses

Acquisition related expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

ResMed

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

ResMed reports robust Q1 performance, eyes margin expansion and partnerships

ResMed's Q1 2023 performance reflects strong revenue growth and a focus on meeting global demand for connected CPAP and APAP devices. The company faces challenges in maintaining gross margins and managing operating expenses but sees opportunities in expanding margins and engaging with new patient segments.

ResMed reports robust Q2 earnings, eyes growth through innovation

ResMed's Q2 2023 earnings call highlighted strong sales growth, increased revenue, and a focus on innovation.
Challenges in supply chain constraints and operating expenses were noted, alongside opportunities in growth drivers.
The company aims to improve lives through respiratory care solutions and digital health innovations by 2025.
ResMed's performance reflects post-COVID awareness of respiratory health importance and customer acceptance of new devices.

ResMed reports robust Q3 performance, eyes global growth opportunities

ResMed's Q3 earnings call highlighted strong financial performance, growth in device revenue and mask sales, and a focus on sustaining profitable growth. The company aims to address challenges in gross margin decline by leveraging opportunities for expansion and reinvestment in growth.

ResMed reports strong Q4 earnings, eyes international growth opportunities

ResMed's Q4 2023 showcased robust financial performance with revenue and earnings growth.
The company's focus on patient care, innovation, and international expansion presents promising opportunities.
Challenges include managing operating expenses, gross margin decline, and pricing dynamics.
Strategic initiatives to improve gross margins and drive revenue growth position ResMed well for the future.

ResMed reports 16% revenue growth in Q1 2024 earnings call

ResMed's Q1 2024 performance showcased revenue growth driven by strong device and mask sales globally.
Despite challenges like margin decline and increased expenses, the company's strategic focus on core business and innovation remains strong.
Opportunities lie in expanding alternative therapies, sustaining growth in devices and masks, and optimizing the SaaS business.
Overall, ResMed is positioned for accelerated profitable growth, prioritizing cost optimization and key initiatives for future success.

ResMed reports strong Q2 earnings, eyes global healthcare expansion

ResMed's Q2 2024 earnings call showcased robust financial performance, strategic priorities in healthcare innovation, and a focus on delivering value through patient care. Despite challenges, the company remains optimistic about growth potential and stakeholder engagement in its mission.

ResMed reports strong Q3 results, eyes global expansion and innovation

ResMed's Q3 earnings call showcased solid financial performance, operational improvements, and a strategic focus on market expansion. With a strong emphasis on innovation and cost discipline, the company is poised for continued growth despite challenges.

ResMed reports robust Q4 growth, eyes digital health opportunities

ResMed's Q4 performance was strong, driven by robust growth and financial stability.
While facing challenges like medication impact and market expansion, opportunities in digital health and partnerships exist.
The company's focus on patient awareness and demand generation remains key to future growth.
Overall, ResMed's strategic initiatives position it well for continued success and innovation.

ResMed excels in Q1 with strong revenue growth and innovation

ResMed's Q1 performance reflects strong revenue growth, product success, and strategic investments.
The company's strengths lie in innovation, supply chain optimization, and proactive growth strategies.
Challenges include competitive pressures, addressing new patient demand, and balancing acquisitions with operational efficiency.
Opportunities abound in digital health, customer partnerships, and expanding patient care pathways.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ResMed reported earnings back on Jan. 28 and the stock has moved lower since then. The move lower has occurred after the company beat EPS and revenue estimates, and posted solid growth numbers from the previous year.

Don't Sleep On ResMed

ResMed (RMD) reported earnings 30 days ago. What's next for the stock?

Why Is ResMed (RMD) Down 10.7% Since Last Earnings Report?

ABIOMED

Chipotle

Fortinet

Illumina

MSCI

Rollins

Teradyne

Under Armour

Zebra Technologies

The market itself is sitting at lofty valuations, but several S&P 500 stocks are extremely overheated. Consider giving these 10 picks a little time to cool off.

10 S&P 500 Stocks to Consider … At Much Lower Prices

Phibro Animal Health

PAHC vs. RMD: Which Stock Is the Better Value Option?

PAHC or RMD: Which Is the Better Value Stock Right Now?

ResMed (RMD) reported second-quarter fiscal 2021 revenues of $800 million, up 9% from a year ago.

ResMed (RMD) Q2 Earnings Surpass Estimates, Margins Rise

ResMed Inc. (RMD) CEO Mick Farrell on Q2 2021 Results - Earnings Call Transcript

ResMed (RMD) delivered earnings and revenue surprises of 15.57% and 3.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Beats Q2 Earnings and Revenue Estimates

Shares of ResMed (NYSE:RMD) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 16.53% year over year to $1.41, which beat the estimate of $1.26.

Recap: ResMed Q2 Earnings

SAN DIEGO--(BUSINESS WIRE)--ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading digital health company, today announced results for its quarter ended December 31, 2020. Second Quarter 2021 Highlights All comparisons are to the prior year period Revenue increased 9% to $800.0 million; up 7% on a constant currency basis GAAP gross margin of 57.8%; non-GAAP gross margin expanded 20 bps to 59.9% Net operating profit increased 12%; non-GAAP operating profit up 16% GAAP diluted earnings per share of $

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2021

On Thursday, January 28, ResMed (NYSE:RMD) will release its latest earnings report. Decipher the announcement with Benzinga's help.

ResMed's Earnings Outlook

American Well Corporation

Teladoc

UnitedHealth Group

Telemedicine is here to stay as the new coronavirus strain triggers a fear psychosis at large, thereby retaining solid demand for telehealth stocks.

New Coronavirus Strain to Keep Telehealth Stocks in Demand

QuidelOrtho Corp

QDEL vs. RMD: Which Stock Is the Better Value Option?

Outset Medical

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysis, is bolstering its board of directors with the appointment of Karen Drexler. Drexler currently serves on the boards of ResMed (NYSE: RMD), a $31B data-driven sleep and respiratory market leader; VIDA Diagnostics, developer of AI-powered lung intelligence and imaging solutions; and Tivic Health, a bioelec

Outset Medical Appoints Karen Drexler to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2021 on Thursday, January 28, 2021, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast. Earnings webcast details: • Location: http://investor.resmed.com • Date: Thursd

ResMed to Report Second Quarter Fiscal 2021 Earnings on January 28, 2021

SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, beginning at approximately 4:30 p.m. (Eastern Standard Time) via webcast. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting http://investor.resmed.com. Conference attendees will be able to access the video webcast via the J.P. M

ResMed Announces Participation in the 39th Annual J.P. Morgan Healthcare Conference

Hologic

IDEXX Laboratories

Owens & Minor

We have selected five MedTech growth stocks with further rooms for improvement in 2021.

5 Soaring MedTech Stocks to Buy for More Growth in 2021

Broadcom

PennyMac Financial Services

Parker-Hannifin

Williams-Sonoma

A steady sales growth is key to survival for any company. Let's check Broadcom (AVGO), PennyMac Financial (PFSI), ResMed (RMD) Williams-Sonoma (WSM) & Parker-Hannifin (PH) as these are likely to witness solid sales growth.

5 Top Stocks With Attractive Sales Growth to Keep an Eye on

NextGen Healthcare Inc

Here are a few stocks which are gaining from the booming digital healthcare space and are likely to maintain momentum in 2021, making them prudent investment choices.

3 Telemedicine Stocks to Gain in 2021 on Digital Health Boom

Thermo Fisher Scientific

West Pharmaceutical Services

Here are a few MedTech stocks which continued to outperform their respective industries amid the pandemic and can turn out to be wise investment choices.

5 MedTech Stocks That Have Outperformed the Industry in 2020

Tandem Diabetes Care

SAN DIEGO--(BUSINESS WIRE)---- $TNDM--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Rajwant (Raj) Singh Sodhi as an independent member of its board of directors effective January 1, 2021. He will succeed Edward Cahill, who has served as a board member for the Company since May 2009. Mr. Sodhi is president of the software as a service (SaaS) business at ResMed (NYSE: RMD, ASX: RMD). He brings to the Tandem board mo

Tandem Diabetes Care Appoints Raj Sodhi to Board of Directors

Is (RMD) Outperforming Other Medical Stocks This Year?

Is ResMed (RMD) Stock Outpacing Its Medical Peers This Year?

Investors continue to be positive about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.

Here's Why You Should Add ResMed (RMD) to Your Portfolio

Align Technology

Insulet

Repligen

Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.

News for ResMed Stock (RMD)